Literature DB >> 20598635

PSA testing for prostate cancer improves survival--but can we do better?

David E Neal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20598635     DOI： 10.1016/S1470-2045(10)70152-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

2.  High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.

Authors:  Yanling Zhang; Xue-Ying Mao; Xiaoyan Liu; Rong-Rong Song; Daniel Berney; Yong-Jie Lu; Guoping Ren
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  A genetic risk assessment for prostate cancer influences patients' risk perception and use of repeat PSA testing: a cross-sectional study in Danish general practice.

Authors:  Jacob Fredsøe; Pia Kirkegaard; Adrian Edwards; Peter Vedsted; Karina Dalsgaard Sørensen; Flemming Bro
Journal:  BJGP Open       Date:  2020-06-23

4.  The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.

Authors:  Jacob Fredsøe; Jan Koetsenruyter; Peter Vedsted; Pia Kirkegaard; Michael Væth; Adrian Edwards; Torben F Ørntoft; Karina D Sørensen; Flemming Bro
Journal:  PLoS Med       Date:  2020-02-07       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.